Last updated: June 17, 2026
SHIONOGI v. LUPIN (2:26-cv-06218): Litigation Summary, Patent Estate Impact, and Generic Launch Risk
Shionogi Inc. v. Lupin Limited, case number 2:26-cv-06218, is a US Hatch-Waxman-style patent litigation matter. The litigation record is not provided in the prompt, so a complete, accurate litigation summary (asserted patents, claims, procedural posture, dates, and outcome) cannot be produced.
What is the case status in SHIONOGI INC. v. LUPIN LIMITED 2:26-cv-06218?
No litigation details are included in the provided input (no docket status, motions schedule, hearing dates, or final orders). A status summary cannot be stated.
What procedural stage is the case in?
No complaint, answer, scheduled deadlines, or case management order information is provided.
When was the lawsuit filed?
The filing date is not provided in the input, beyond the case number.
Which patents are asserted in SHIONOGI v. LUPIN 2:26-cv-06218?
The asserted patent numbers and claims are not included in the provided input. A patent-assertion map cannot be generated.
What is the Orange Book hook for the asserted patents?
No drug name, NDA/BLA number, or Orange Book listing is provided.
Are formulation patents, method-of-use patents, or manufacturing patents asserted?
No claim types or patent classifications are provided.
What FDA Paragraph IV certification and ANDA/BLA context drives SHIONOGI v. LUPIN 2:26-cv-06218?
No ANDA/BLA number, listed drug, or Paragraph IV certifications are provided in the input. The FDA-triggering facts cannot be summarized.
Is the challenge under Paragraph IV, 5-year, 3-year, or pediatric exclusivity?
No certifications or exclusivity frameworks are provided.
What dosage forms and strengths are at issue?
No product configuration is provided.
What does the claim construction and infringement theory look like?
No claim charts, infringement allegations, or claim construction order excerpts are provided in the input.
What are the key infringement allegations?
No infringement content is provided.
What defenses has Lupin raised?
No defenses or invalidity content is provided.
How strong is the SHIONOGI patent estate in this dispute?
No asserted patent list, independent claims, priority dates, prosecution history, or validity history is provided, so strength cannot be analyzed.
What is the expiration timing for the asserted patents?
No expiration or term data is provided.
Are there reissue, continuation, or terminal disclaimer factors?
No prosecution data is provided.
What litigation milestones matter for a generic entry timeline?
No scheduling order, preliminary injunction posture, or trial dates are provided.
Has the court set a Markman hearing?
No Markman schedule is provided.
Is there a preliminary injunction request?
No injunction request content is provided.
What settlements or consent judgments govern SHIONOGI v. LUPIN 2:26-cv-06218?
No settlement agreement, consent judgment, or dismissal order is provided in the input.
Are there authorized generic or license terms?
No license terms are provided.
Do any stipulations affect FDA approval dates?
No stipulations are provided.
How does this case affect FDA approval or potential market launch?
No FDA status, tentative approval timing, launch triggers, or stay dates are provided.
Is there an automatic 30-month stay?
No ANDA filing and date triggers are provided.
Does the litigation posture control the launch date?
No court rulings are provided.
Competitive landscape: how does SHIONOGI v. LUPIN compare with similar Shionogi Hatch-Waxman disputes?
No comparable case set is provided, so a relative comparison cannot be produced from the prompt.
Which other generics are likely watching this docket?
No competitor list is provided.
Do similar Shionogi patents show up across other litigations?
No cross-case data is provided.
Key Takeaways
- The prompt provides only the caption and case number (2:26-cv-06218).
- A litigation summary that covers asserted patents, procedural status, key dates, infringement and invalidity positions, and any injunction or settlement terms requires docket-specific facts that are not present.
FAQs
-
What does case number 2:26-cv-06218 indicate about the court and venue?
The prompt does not include venue-specific docket metadata beyond the case number.
-
Does SHIONOGI v. LUPIN 2:26-cv-06218 involve an ANDA Paragraph IV filing?
The prompt does not include FDA certification details.
-
Which specific patents are listed as infringed in this case?
No asserted patent numbers are included in the prompt.
-
Has the court entered any injunction or stay in this matter?
No orders are included in the prompt.
-
What is the expected generic entry risk for Lupin based on 2:26-cv-06218?
No scheduling order, trial date, or settlement/injunction outcome is included in the prompt.
References
- Bloomberg Law database. (Not provided in the prompt.)
- United States District Court docket for Shionogi Inc. v. Lupin Limited, 2:26-cv-06218. (Not provided in the prompt.)
